Dienogest interrupts the chemokine signalling axis in endometriotic lesions with resistant signatures providing novel opportunities for personalised treatment.

In: Research Square · 2026 · doi:10.21203/rs.3.rs-8096027/v1 · W7123685302
preprint OA: green CC0
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-06-13 ⓘ

Dienogest disrupted the chemokine signaling axis in endometriotic lesions with resistant signatures, presenting new avenues for personalized treatment approaches.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

The preprint investigated how dienogest (DNG) affects endometriotic lesions and how non-response signatures relate to stromal/epithelial composition, using archival patient samples with clinical data, single-nuclei sequencing, in silico predictions, and patient-derived organoid high-content drug screening. The authors report that DNG represses the inflammatory phenotype of deeply infiltrating endometriotic lesions by disrupting the chemokine signalling axis, while refractory patients show altered cell composition, aberrant progesterone receptor co-repressor signalling, and enhanced TGF-β–mediated fibrosis. Computational drug prioritization suggested glucocorticoid receptor agonists for stroma/immune-rich lesions and HSP90 or NF-κB inhibitors for epithelial-dominant lesions, with some candidates validated in organoids. The paper is a preprint under review, and its key limitation explicitly noted is that it has not been peer reviewed. This paper is centrally about endometriosis — it dissects dienogest’s mechanism in endometriotic lesions and proposes personalised stratification strategies for refractory disease.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Progestins are important first line and adjuvant medications for endometriosis, yet their efficacy varies among patients. Dienogest (DNG), a 4th generation progestin, is one of the most prescribed and successful progestins, although a subset of patients remain refractory to treatment. A prospective method to match patients to DNG, or other treatments could significantly improve patient outcomes. We employed a multidisciplinary approach using archival patient samples, clinical data, single nuclei sequencing, in silico prediction and high-content organoid drug screening to investigate DNG's impact on endometriotic lesions, signatures of non-response, and treatment options for refractory patients. We found DNG represses the inflammatory phenotype of deeply infiltrating endometriotic lesions by disrupting the chemokine signalling axis. Refractory patients displayed altered epithelial and stromal cell composition, aberrant progesterone receptor co-repressor signalling and enhanced TGF-B mediated fibrosis. Computational drug predictions identified potential therapies for refractory cases, including glucocorticoid receptor agonists for stroma- and immune-rich lesions, and HSP90 or NF-κB inhibitors for epithelial-dominant lesions, the activity of which were validated in high content screening of patient derived organoids. Notably some progestins already approved for endometriosis management possess off-target glucocorticoid activity, providing immediate potential for personalized treatment selection.
Full text 32,328 characters · extracted from preprint-html · click to expand
Dienogest interrupts the chemokine signalling axis in endometriotic lesions with resistant signatures providing novel opportunities for personalised treatment. | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Dienogest interrupts the chemokine signalling axis in endometriotic lesions with resistant signatures providing novel opportunities for personalised treatment. Brett McKinnon, Lea Duempelmann, Jitka Skrabalova, Sugarniya Subramaniam, and 12 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8096027/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted You are reading this latest preprint version Abstract Progestins are important first line and adjuvant medications for endometriosis, yet their efficacy varies among patients. Dienogest (DNG), a 4th generation progestin, is one of the most prescribed and successful progestins, although a subset of patients remain refractory to treatment. A prospective method to match patients to DNG, or other treatments could significantly improve patient outcomes. We employed a multidisciplinary approach using archival patient samples, clinical data, single nuclei sequencing, in silico prediction and high-content organoid drug screening to investigate DNG's impact on endometriotic lesions, signatures of non-response, and treatment options for refractory patients. We found DNG represses the inflammatory phenotype of deeply infiltrating endometriotic lesions by disrupting the chemokine signalling axis. Refractory patients displayed altered epithelial and stromal cell composition, aberrant progesterone receptor co-repressor signalling and enhanced TGF-B mediated fibrosis. Computational drug predictions identified potential therapies for refractory cases, including glucocorticoid receptor agonists for stroma- and immune-rich lesions, and HSP90 or NF-κB inhibitors for epithelial-dominant lesions, the activity of which were validated in high content screening of patient derived organoids. Notably some progestins already approved for endometriosis management possess off-target glucocorticoid activity, providing immediate potential for personalized treatment selection. Biological sciences/Molecular biology/Transcriptomics Health sciences/Diseases/Reproductive disorders/Endocrine reproductive disorders Biological sciences/Cell biology/Mechanisms of disease Endometriosis Dienogest single nuclei organoids CMAP glucocorticoids HSP90 NF- κB High content screening drug screening Luminespib Triptolide Parthenolide Full Text Additional Declarations All patients provided written informed consent for the collection and use of their samples for research purposes, in accordance with approved institutional ethics protocols. Yes there is potential Competing Interest. I am on the scientific advisory board for Maipl Therapeutics. I have received no compensation or input from Maipl for the conduct of this study. I have a project with Bayer. I receive no compensation from Bayer for this project. Supplementary Files sTable1.xlsx Supplementary Table 1: sTable3.xlsx Supplementary Table 3: sTable9.xlsx Supplementary Table 9: sTable7.xlsx Supplementary Table 7: sTable6.xlsx Supplementary Table 6: sTable11.xlsx Supplementary Table 11: sTable10.xlsx Supplementary Table 10: sTable2.xlsx Supplementary Table 2: sTable5.xlsx Supplementary Table 5: sTable8.xlsx Supplementary Table 8: sTable4.xlsx Supplementary Table 4: Cite Share Download PDF Status: Under Review Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8096027","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":570402304,"identity":"cc637a19-c9f5-4472-9648-9e0987793456","order_by":0,"name":"Brett McKinnon","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA1UlEQVRIiWNgGAWjYBACAyBmbACRDMwHGMAcErSwJZCiBczkMSBOizkDd+LHGQV38vile75JvGGwkd1wgPmZBD4tlg28myU3GDwrlpxzdpvkHIY04w0H2MzwajE4wLuN8YHB4cQNN3K3SfMwABkHGIjWkvMMqOU/UAv7N8JaNkC0sAG1HABq4cFvi2Uz0C8zgFpmzkgztpxjkGw88zBPsQU+LebsvRs/9vw5nNgvkfzwxpsKO9m+4+0bb+DTwsCMzAFHDTMOldgBD0mqR8EoGAWjYKQAAHwxS0aWMAENAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0002-9881-1252","institution":"Institute for Molecular Bioscience","correspondingAuthor":true,"prefix":"","firstName":"Brett","middleName":"","lastName":"McKinnon","suffix":""},{"id":570402305,"identity":"75917076-4aeb-472e-bc67-9621008e4fe4","order_by":1,"name":"Lea Duempelmann","email":"","orcid":"https://orcid.org/0000-0002-5775-5186","institution":"University of Berne","correspondingAuthor":false,"prefix":"","firstName":"Lea","middleName":"","lastName":"Duempelmann","suffix":""},{"id":570402306,"identity":"6fbccb33-2e10-4d7e-a777-5a66c51a08d8","order_by":2,"name":"Jitka Skrabalova","email":"","orcid":"","institution":"Inselspital","correspondingAuthor":false,"prefix":"","firstName":"Jitka","middleName":"","lastName":"Skrabalova","suffix":""},{"id":570402307,"identity":"2b567df8-cfcb-4f25-b771-bf1ba68f039f","order_by":3,"name":"Sugarniya Subramaniam","email":"","orcid":"","institution":"Institute for Molecular Bioscience","correspondingAuthor":false,"prefix":"","firstName":"Sugarniya","middleName":"","lastName":"Subramaniam","suffix":""},{"id":570402308,"identity":"bb4bcb88-a71a-4a8b-ac65-c36a2b93c7a8","order_by":4,"name":"Lea Taylor","email":"","orcid":"https://orcid.org/0000-0001-5066-6941","institution":"Univeristy of Bern","correspondingAuthor":false,"prefix":"","firstName":"Lea","middleName":"","lastName":"Taylor","suffix":""},{"id":570402309,"identity":"7685f72e-6902-4112-a772-997fba20fb47","order_by":5,"name":"Sharat Atluri","email":"","orcid":"","institution":"Institute for Molecular Bioscience","correspondingAuthor":false,"prefix":"","firstName":"Sharat","middleName":"","lastName":"Atluri","suffix":""},{"id":570402310,"identity":"f2e142da-6d0b-4eae-89f6-cd0646c0c8dc","order_by":6,"name":"Solal Chauquet","email":"","orcid":"","institution":"Institute for Molecular Bioscience","correspondingAuthor":false,"prefix":"","firstName":"Solal","middleName":"","lastName":"Chauquet","suffix":""},{"id":570402311,"identity":"39f0c946-a504-4a46-9936-dd43e68fbe49","order_by":7,"name":"Grant Montgomery","email":"","orcid":"https://orcid.org/0000-0002-4140-8139","institution":"The University of Queensland","correspondingAuthor":false,"prefix":"","firstName":"Grant","middleName":"","lastName":"Montgomery","suffix":""},{"id":570402312,"identity":"096277f3-3d31-4691-a819-e29a2324a70c","order_by":8,"name":"Keisuke Tanaka","email":"","orcid":"","institution":"Royal Brisbane and Women's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Keisuke","middleName":"","lastName":"Tanaka","suffix":""},{"id":570402313,"identity":"44c3aa1b-ce6d-48d7-82d7-ae75774f5fd8","order_by":9,"name":"Susanne Ramm","email":"","orcid":"","institution":"The University of Melbourne, Sir Peter MacCallum Department of Oncology, Victorian Comprehensive Cancer Centre","correspondingAuthor":false,"prefix":"","firstName":"Susanne","middleName":"","lastName":"Ramm","suffix":""},{"id":570402314,"identity":"7c6a5f7a-38e9-44c6-b38d-2141c9b8a3e1","order_by":10,"name":"Jennii Luu","email":"","orcid":"","institution":"The University of Melbourne, Sir Peter MacCallum Department of Oncology, Victorian Comprehensive Cancer Centre","correspondingAuthor":false,"prefix":"","firstName":"Jennii","middleName":"","lastName":"Luu","suffix":""},{"id":570402315,"identity":"1f8141b2-4445-4199-8f7b-c1f9ba9b17bd","order_by":11,"name":"Kaylene Simpson","email":"","orcid":"https://orcid.org/0000-0001-9136-1781","institution":"Peter MacCallum Cancer Centre","correspondingAuthor":false,"prefix":"","firstName":"Kaylene","middleName":"","lastName":"Simpson","suffix":""},{"id":570402316,"identity":"caa568e9-412c-4cd3-9b3a-6438bd77c0f6","order_by":12,"name":"Sonia Shah","email":"","orcid":"https://orcid.org/0000-0001-5860-4526","institution":"The University of Queensland","correspondingAuthor":false,"prefix":"","firstName":"Sonia","middleName":"","lastName":"Shah","suffix":""},{"id":570402317,"identity":"060e6ef9-1511-4735-b666-dcf434cfffe6","order_by":13,"name":"Akwasi Amoako","email":"","orcid":"","institution":"Royal Brisbane and Women's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Akwasi","middleName":"","lastName":"Amoako","suffix":""},{"id":570402318,"identity":"4f8fcd48-bd60-40b4-9069-2b43413e216b","order_by":14,"name":"Michael Mueller","email":"","orcid":"","institution":"University of Bern","correspondingAuthor":false,"prefix":"","firstName":"Michael","middleName":"","lastName":"Mueller","suffix":""},{"id":570402319,"identity":"198fdff8-4287-42f0-bdb3-4c15d175b3d7","order_by":15,"name":"Konstantinos Nirgianakis","email":"","orcid":"","institution":"Inselspital","correspondingAuthor":false,"prefix":"","firstName":"Konstantinos","middleName":"","lastName":"Nirgianakis","suffix":""}],"badges":[],"createdAt":"2025-11-12 11:55:46","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8096027/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8096027/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":100367041,"identity":"14e052a3-689f-4777-9a0c-ab4f8b9b4510","added_by":"auto","created_at":"2026-01-16 07:56:44","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":6622813,"visible":true,"origin":"","legend":"","description":"","filename":"Manuscriptwithfigures.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/0fbac943096f5ebaa8190ad4.pdf"},{"id":100144141,"identity":"2ac87ccb-76e3-40be-b038-db67829fa2dc","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":405666,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/0997b58b8c4c14a0f9442c17.pdf"},{"id":100366842,"identity":"d2a067ce-3ed5-437f-bfb1-7208b9e3f165","added_by":"auto","created_at":"2026-01-16 07:56:35","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":620495,"visible":true,"origin":"","legend":"","description":"","filename":"Figure2.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/c0109121442206ae3346b3ea.pdf"},{"id":100144148,"identity":"357d27a4-1d96-471f-bfae-88bb2e777942","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"pdf","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":412325,"visible":true,"origin":"","legend":"","description":"","filename":"Figure3.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/f913544a31972f50b42e1762.pdf"},{"id":100368379,"identity":"28762566-ab0e-4208-b4d3-c0c67e3306dd","added_by":"auto","created_at":"2026-01-16 07:57:54","extension":"pdf","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":329078,"visible":true,"origin":"","legend":"","description":"","filename":"Figure5.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/98308ef9206bf2cf873742ab.pdf"},{"id":100366930,"identity":"2ce0ea9f-9407-4ce7-b7bb-f19bfc95ad42","added_by":"auto","created_at":"2026-01-16 07:56:40","extension":"pdf","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":543025,"visible":true,"origin":"","legend":"","description":"","filename":"Figure6.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/9cb4f936450d10b3a6b5af7f.pdf"},{"id":100144154,"identity":"ed319032-335b-46b4-a541-d49784de00ab","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"pdf","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":537842,"visible":true,"origin":"","legend":"","description":"","filename":"Figure7.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/e668d802246e4500c6274736.pdf"},{"id":100144160,"identity":"c6e20162-9f99-4d50-aed9-b981cc9c7a73","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"pdf","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":408144,"visible":true,"origin":"","legend":"","description":"","filename":"figure4.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/04c508d734a74d59340d0a91.pdf"},{"id":100366957,"identity":"8e3f68af-4684-4b34-a743-b7e35af0eb0c","added_by":"auto","created_at":"2026-01-16 07:56:41","extension":"pdf","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":408151,"visible":true,"origin":"","legend":"","description":"","filename":"sFigure1.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/a37951636715fa484aaa532c.pdf"},{"id":100366419,"identity":"250eb6e7-ab27-45bc-b7c7-12e20784a446","added_by":"auto","created_at":"2026-01-16 07:56:18","extension":"pdf","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":454345,"visible":true,"origin":"","legend":"","description":"","filename":"sFigure2.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/f6481dbb3780fdd8c8653a17.pdf"},{"id":100368566,"identity":"a9e3fe41-1513-4c63-b147-c77a21b17451","added_by":"auto","created_at":"2026-01-16 07:58:06","extension":"pdf","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":610861,"visible":true,"origin":"","legend":"","description":"","filename":"sFigure3.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/c615bffa36831cbc4cec73bc.pdf"},{"id":100367677,"identity":"a67f74b5-e194-4b4f-8a63-cebf995d3fc2","added_by":"auto","created_at":"2026-01-16 07:57:13","extension":"pdf","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":944506,"visible":true,"origin":"","legend":"","description":"","filename":"sFigure4.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/534d3ba50d70a3c0ee5159ff.pdf"},{"id":100144159,"identity":"3ac6db03-5443-4b41-b2ee-34ca72c1c076","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"pdf","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":431011,"visible":true,"origin":"","legend":"","description":"","filename":"sFigure5.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/5db526706e23c10666a95b04.pdf"},{"id":100368333,"identity":"6b0ecf2a-ac7e-4965-8c95-2288c606fbc2","added_by":"auto","created_at":"2026-01-16 07:57:51","extension":"pdf","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":240717,"visible":true,"origin":"","legend":"","description":"","filename":"sFigure6.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/4d7ec96f987a52073eec43ff.pdf"},{"id":100367416,"identity":"f9ebe598-1904-4690-a74c-daed3be9cff7","added_by":"auto","created_at":"2026-01-16 07:57:02","extension":"json","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":15465,"visible":true,"origin":"","legend":"","description":"","filename":"NCOMMS2595424T.json","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/52a2e818d49fd48bc326b10f.json"},{"id":100367040,"identity":"4c59cd31-b02f-4a90-adf2-0bea0622223f","added_by":"auto","created_at":"2026-01-16 07:56:44","extension":"xlsx","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":10806,"visible":true,"origin":"","legend":"","description":"","filename":"sTable1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/240068439f62b66f1dd41052.xlsx"},{"id":100367457,"identity":"b1e1caed-2646-4680-86cd-3221eb746d52","added_by":"auto","created_at":"2026-01-16 07:57:05","extension":"xlsx","order_by":16,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":27633,"visible":true,"origin":"","legend":"","description":"","filename":"sTable10.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/d661122954ae3a1116e42f60.xlsx"},{"id":100367686,"identity":"c288fa45-3f95-4d38-926f-3f6f80d75acf","added_by":"auto","created_at":"2026-01-16 07:57:13","extension":"xlsx","order_by":17,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":377925,"visible":true,"origin":"","legend":"","description":"","filename":"sTable11.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/bcb7067bd34cd00f5783d06e.xlsx"},{"id":100144171,"identity":"c52b1e79-07b0-4921-9f37-8cce742707e8","added_by":"auto","created_at":"2026-01-13 12:10:05","extension":"xlsx","order_by":18,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":52763,"visible":true,"origin":"","legend":"","description":"","filename":"sTable2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/fb8a5851e8e31f41d031d99a.xlsx"},{"id":100144166,"identity":"f3e40470-6e69-4069-a499-b2a61222ce42","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"xlsx","order_by":19,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":51961,"visible":true,"origin":"","legend":"","description":"","filename":"sTable3.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/9ced231e71108ce35c373383.xlsx"},{"id":100144178,"identity":"5e8e59c5-b5a6-42e5-aa37-b89ba159ecc0","added_by":"auto","created_at":"2026-01-13 12:10:06","extension":"xlsx","order_by":20,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":15806,"visible":true,"origin":"","legend":"","description":"","filename":"sTable4.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/b6c194880e2b60b2db0098ff.xlsx"},{"id":100368152,"identity":"cf816965-09b6-45ef-b561-f02bad6757b0","added_by":"auto","created_at":"2026-01-16 07:57:39","extension":"xlsx","order_by":21,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":16996,"visible":true,"origin":"","legend":"","description":"","filename":"sTable5.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/5045c30cee1566911008e1e6.xlsx"},{"id":100367684,"identity":"d81eb6a7-2f58-45d2-bc12-9bd5455b7c12","added_by":"auto","created_at":"2026-01-16 07:57:13","extension":"xlsx","order_by":22,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":165395,"visible":true,"origin":"","legend":"","description":"","filename":"sTable6.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/e4266f040d821debb832c82d.xlsx"},{"id":100367865,"identity":"4709acd3-3c7f-4fd6-9cc0-59d263213890","added_by":"auto","created_at":"2026-01-16 07:57:24","extension":"xlsx","order_by":23,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":169653,"visible":true,"origin":"","legend":"","description":"","filename":"sTable7.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/f9e987b1821fe498be73fb08.xlsx"},{"id":100144161,"identity":"4638ad70-1e05-44de-9729-ca3aba9be3cc","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"xlsx","order_by":24,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":68816,"visible":true,"origin":"","legend":"","description":"","filename":"sTable8.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/0b3b288bdc31a263357c9eea.xlsx"},{"id":100144173,"identity":"f1d31b3c-3fe8-4377-81c3-7c88d5aff823","added_by":"auto","created_at":"2026-01-13 12:10:05","extension":"xlsx","order_by":25,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":40634,"visible":true,"origin":"","legend":"","description":"","filename":"sTable9.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/bafd7fdeaa7e1d11ea00fe95.xlsx"},{"id":100406294,"identity":"1133b7d5-afed-438b-8dbd-1a26917a2a27","added_by":"auto","created_at":"2026-01-16 12:59:59","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":4104050,"visible":true,"origin":"","legend":"Article File","description":"","filename":"Manuscriptwithfigures.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1_covered_c0ba28f0-405e-44bb-83fc-c201d74d6174.pdf"},{"id":100366758,"identity":"760e9372-8219-4ca6-a3ef-4f881453c24d","added_by":"auto","created_at":"2026-01-16 07:56:31","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":10806,"visible":true,"origin":"","legend":"Supplementary Table 1:","description":"","filename":"sTable1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/dce587abd82e49950153ca08.xlsx"},{"id":100366661,"identity":"fc0b674a-ca92-4afc-9456-edd26fbd23f7","added_by":"auto","created_at":"2026-01-16 07:56:26","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":51961,"visible":true,"origin":"","legend":"Supplementary Table 3:","description":"","filename":"sTable3.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/e8c6aa96b2df7120f5f711e9.xlsx"},{"id":100366722,"identity":"c65c251b-3f0c-4d4d-b212-067f1105ad9b","added_by":"auto","created_at":"2026-01-16 07:56:30","extension":"xlsx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":40634,"visible":true,"origin":"","legend":"Supplementary Table 9:","description":"","filename":"sTable9.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/84f81a9f2d13c4bc0adcef95.xlsx"},{"id":100144145,"identity":"1a478680-3ec7-4be5-a3b1-070e3210f2b7","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"xlsx","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":169653,"visible":true,"origin":"","legend":"Supplementary Table 7:","description":"","filename":"sTable7.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/4398ae587ed2906fcbe1de8f.xlsx"},{"id":100144179,"identity":"9f9b0273-d1a9-4bdb-830c-7e3e67e95a52","added_by":"auto","created_at":"2026-01-13 12:10:06","extension":"xlsx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":165395,"visible":true,"origin":"","legend":"Supplementary Table 6:","description":"","filename":"sTable6.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/9ca5a08b015ea594c1f9026f.xlsx"},{"id":100368146,"identity":"f9d25f10-cc70-4f75-84fa-6597a589619b","added_by":"auto","created_at":"2026-01-16 07:57:38","extension":"xlsx","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":377925,"visible":true,"origin":"","legend":"Supplementary Table 11:","description":"","filename":"sTable11.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/daac9f19bd1395056e258762.xlsx"},{"id":100144163,"identity":"1b92e3cf-857b-47af-91a2-b526ff453a7b","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"xlsx","order_by":7,"title":"","display":"","copyAsset":false,"role":"supplement","size":27633,"visible":true,"origin":"","legend":"Supplementary Table 10:","description":"","filename":"sTable10.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/7936fef3186e08f693aa0e25.xlsx"},{"id":100144165,"identity":"4036fd6b-dcd0-45ae-88f5-21518bd7c0c0","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"xlsx","order_by":8,"title":"","display":"","copyAsset":false,"role":"supplement","size":52763,"visible":true,"origin":"","legend":"Supplementary Table 2:","description":"","filename":"sTable2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/03a606b9d732bc1af40923fb.xlsx"},{"id":100367021,"identity":"a7b584be-3695-41fa-82dd-9ccea7e3c22e","added_by":"auto","created_at":"2026-01-16 07:56:44","extension":"xlsx","order_by":9,"title":"","display":"","copyAsset":false,"role":"supplement","size":16996,"visible":true,"origin":"","legend":"Supplementary Table 5:","description":"","filename":"sTable5.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/f6f59bd27a7040307463424d.xlsx"},{"id":100144157,"identity":"4e589db5-7796-4fbc-9d2c-597f5860a1b8","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"xlsx","order_by":10,"title":"","display":"","copyAsset":false,"role":"supplement","size":68816,"visible":true,"origin":"","legend":"Supplementary Table 8:","description":"","filename":"sTable8.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/25e4e51e81786f336ac9e323.xlsx"},{"id":100144152,"identity":"e69f1771-d900-4fb4-a702-13b73a79d839","added_by":"auto","created_at":"2026-01-13 12:10:04","extension":"xlsx","order_by":11,"title":"","display":"","copyAsset":false,"role":"supplement","size":15806,"visible":true,"origin":"","legend":"Supplementary Table 4:","description":"","filename":"sTable4.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8096027/v1/ae08dfa540cde74e34b2249d.xlsx"}],"financialInterests":"\u003cp\u003eAll patients provided written informed consent for the collection and use of their samples for research purposes, in accordance with approved institutional ethics protocols.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eYes\u003c/strong\u003e there is potential Competing Interest. I am on the scientific advisory board for Maipl Therapeutics. I have received no compensation or input from Maipl for the conduct of this study. I have a project with Bayer. I receive no compensation from Bayer for this project.\u003c/p\u003e","formattedTitle":"Dienogest interrupts the chemokine signalling axis in endometriotic lesions with resistant signatures providing novel opportunities for personalised treatment.","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"nature-portfolio","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"","title":"Nature Portfolio","twitterHandle":"","acdcEnabled":false,"dfaEnabled":false,"editorialSystem":"ejp","reportingPortfolio":"","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Endometriosis, Dienogest, single nuclei, organoids, CMAP, glucocorticoids, HSP90, NF- κB, High content screening, drug screening, Luminespib, Triptolide, Parthenolide","lastPublishedDoi":"10.21203/rs.3.rs-8096027/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8096027/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"Progestins are important first line and adjuvant medications for endometriosis, yet their efficacy varies among patients. Dienogest (DNG), a 4th generation progestin, is one of the most prescribed and successful progestins, although a subset of patients remain refractory to treatment. A prospective method to match patients to DNG, or other treatments could significantly improve patient outcomes. We employed a multidisciplinary approach using archival patient samples, clinical data, single nuclei sequencing, in silico prediction and high-content organoid drug screening to investigate DNG's impact on endometriotic lesions, signatures of non-response, and treatment options for refractory patients. We found DNG represses the inflammatory phenotype of deeply infiltrating endometriotic lesions by disrupting the chemokine signalling axis. Refractory patients displayed altered epithelial and stromal cell composition, aberrant progesterone receptor co-repressor signalling and enhanced TGF-B mediated fibrosis. Computational drug predictions identified potential therapies for refractory cases, including glucocorticoid receptor agonists for stroma- and immune-rich lesions, and HSP90 or NF-κB inhibitors for epithelial-dominant lesions, the activity of which were validated in high content screening of patient derived organoids. Notably some progestins already approved for endometriosis management possess off-target glucocorticoid activity, providing immediate potential for personalized treatment selection.","manuscriptTitle":"Dienogest interrupts the chemokine signalling axis in endometriotic lesions with resistant signatures providing novel opportunities for personalised treatment.","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-01-13 12:09:41","doi":"10.21203/rs.3.rs-8096027/v1","editorialEvents":[],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"nature-communications","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"NCOMMS","sideBox":"Learn more about [Nature Communications](http://www.nature.com/ncomms/)","snPcode":"","submissionUrl":"https://mts-ncomms.nature.com/","title":"Nature Communications","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature Communications","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"fef02f00-bee2-4ff1-9af7-de7f6256596a","owner":[],"postedDate":"January 13th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":60697151,"name":"Biological sciences/Molecular biology/Transcriptomics"},{"id":60697152,"name":"Health sciences/Diseases/Reproductive disorders/Endocrine reproductive disorders"},{"id":60697153,"name":"Biological sciences/Cell biology/Mechanisms of disease"}],"tags":[],"updatedAt":"2026-03-20T13:31:35+00:00","versionOfRecord":[],"versionCreatedAt":"2026-01-13 12:09:41","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8096027","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8096027","identity":"rs-8096027","version":["v1"]},"buildId":"B-jG_2CBjPDmsCi4Wdhf-","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: preprint-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-09-25T06:31:40.285045+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK